Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Gilead Sciences
Novartis
Cogent Biosciences, Inc.
Karyopharm Therapeutics Inc
Autolus Limited
AbbVie
Phoenix Children's Hospital
Orca Biosystems, Inc.
Regeneron Pharmaceuticals
Juno Therapeutics, a Subsidiary of Celgene
Novartis
Gilead Sciences
Duke University
AVM Biotechnology Inc
Kura Oncology, Inc.
Kura Oncology, Inc.
Janssen Biotech, Inc.
University of Texas Southwestern Medical Center
Eli Lilly and Company
BeiGene
Novartis
AbbVie
Alexion Pharmaceuticals, Inc.
Gilead Sciences
Atara Biotherapeutics
Genmab
EQRx International, Inc.
AbbVie
Merck Sharp & Dohme LLC
Novartis
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Gilead Sciences
Jazz Pharmaceuticals
University of California, San Francisco
ADC Therapeutics S.A.
Seagen Inc.
MorphoSys AG
Molecular Templates, Inc.
ERYtech Pharma
Janssen-Cilag Farmaceutica Ltda.
Barbara Ann Karmanos Cancer Institute
Sanofi
Gilead Sciences
BTG International Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie